LTR Pharma Limited (ASX: LTP)

Australia flag Australia · Delayed Price · Currency is AUD
1.225
+0.005 (0.41%)
Nov 21, 2024, 2:42 PM AEST
282.81%
Market Cap 187.64M
Revenue (ttm) 49.00K
Net Income (ttm) -6.95M
Shares Out 153.80M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,358
Open 1.205
Previous Close 1.220
Day's Range 1.205 - 1.240
52-Week Range 0.245 - 2.160
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 27, 2024

About LTR Pharma

LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LTP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.